AR125935A1 - ERBB3-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL THAT EXPRESSES THE SAME - Google Patents
ERBB3-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL THAT EXPRESSES THE SAMEInfo
- Publication number
- AR125935A1 AR125935A1 ARP220101354A ARP220101354A AR125935A1 AR 125935 A1 AR125935 A1 AR 125935A1 AR P220101354 A ARP220101354 A AR P220101354A AR P220101354 A ARP220101354 A AR P220101354A AR 125935 A1 AR125935 A1 AR 125935A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- chimeric antigen
- antigen receptor
- seq
- erbb3
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 11
- 210000002865 immune cell Anatomy 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 3
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 abstract 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 abstract 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 abstract 2
- 230000004068 intracellular signaling Effects 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 102100027207 CD27 antigen Human genes 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100035793 CD83 antigen Human genes 0.000 abstract 1
- 102100037904 CD9 antigen Human genes 0.000 abstract 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 abstract 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 abstract 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 abstract 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 abstract 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 abstract 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 abstract 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 abstract 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 abstract 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 abstract 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 abstract 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 abstract 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 abstract 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 abstract 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 abstract 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 abstract 1
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 abstract 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 abstract 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 abstract 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 abstract 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 abstract 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 abstract 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 abstract 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 abstract 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 abstract 1
- -1 ICOS (CD278) Proteins 0.000 abstract 1
- 102100025390 Integrin beta-2 Human genes 0.000 abstract 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 abstract 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 abstract 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 abstract 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 abstract 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 abstract 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 abstract 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 abstract 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 abstract 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 abstract 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 abstract 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 abstract 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 abstract 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 abstract 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 abstract 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
Reivindicación 1: Un receptor de antígeno quimérico (CAR), que comprende: un dominio de unión extracelular que comprende un dominio de unión a antígenos que se une específicamente a ErbB3 (Erb-B2 receptor tirosina quinasa 3); un dominio transmembrana; y un dominio de señalización intracelular. Reivindicación 2: El receptor de antígeno quimérico según la reivindicación 1, en el que el dominio de unión específicamente unido a ErbB3 es un fragmento variable de cadena única (scFv) de un anticuerpo anti-ErbB3, que comprende: un CDR1 de cadena pesada seleccionado del grupo formado por SEQ ID Nº 1, 9, 17, 25 y 33, un CDR2 de cadena pesada seleccionado del grupo formado por SEQ ID Nº 2, 10, 18, 26 y 34, un CDR3 de cadena pesada seleccionado del grupo formado por SEQ ID Nº 3, 11, 19, 27 y 35, un CDR1 de cadena ligera seleccionado del grupo formado por LOS SEQ ID Nº 4, 12, 20, 28 y 36, un CDR2 de cadena ligera seleccionado del grupo formado por SEQ ID Nº 5, 13, 21, 29 y 37, y un CDR3 de cadena ligera seleccionado del grupo formado por los SEQ ID Nº 6, 14, 22, 30 y 38. Reivindicación 3: El receptor de antígeno quimérico según la reivindicación 1, en el que el dominio de unión específicamente unido a ErbB3 es un fragmento variable de cadena única (scFv) de un anticuerpo anti-ErbB3 que comprende una región variable de cadena pesada que comprende una secuencia seleccionada del grupo formado por los SEQ ID Nº 7, 15, 23, 31 y 39. Reivindicación 4: El receptor de antígeno quimérico según la reivindicación 1, en el que el dominio de unión que se une específicamente a ErbB3 es un fragmento variable de cadena única (scFv) de un anticuerpo anti-ErbB3 que comprende una región variable de cadena ligera que comprende una secuencia seleccionada del grupo formado por los SEQ ID Nº 8, 16, 24, 32 y 40. Reivindicación 5: El receptor de antígeno quimérico según la reivindicación 1, en el que el dominio de unión extracelular comprende además al menos uno de un péptido señal y/o una bisagra. Reivindicación 6: El receptor de antígeno quimérico según la reivindicación 5, en el que el péptido señal es un péptido señal de CD8. Reivindicación 7: El receptor de antígeno quimérico según la reivindicación 5, en el que la bisagra comprende una bisagra de CD28 o CD8. Reivindicación 8: El receptor de antígeno quimérico según la reivindicación 1, en el que el dominio transmembrana se selecciona del grupo formado por una cadena de receptores de células T (TCR) alfa (a), beta (b) o zeta (z), CD28, CD3 épsilon (e), CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 y CD154. Reivindicación 9: El receptor de antígeno quimérico según la reivindicación 1, en el que el dominio de señalización intracelular comprende: un dominio de señalización primario seleccionado del grupo formado por receptor de células T (TCR) zeta (z), FcR gamma (g), FcR beta (b), CD3 gamma (g), CD3 delta (d), CD3 épsilon (e), CD3 zeta (z), CD5, CD22, CD79a, CD79b y CD66d; y/o un dominio de señalización coestimuladora seleccionado del grupo formado por CD2, CD7, CD27, CD28, CD30, CD40, 4-1BB (CD137), OX40 (CD134), CDS, ICAM-1, ICOS (CD278), LFA-1 (CD11a / CD18), GITR, MyD88, DAP10, DAP12, 5 PD-1, LIGHT, NKG2C, B7-H3, y un ligando específicamente unido a CD83.Claim 1: A chimeric antigen receptor (CAR), comprising: an extracellular binding domain comprising an antigen binding domain that specifically binds ErbB3 (Erb-B2 receptor tyrosine kinase 3); a transmembrane domain; and an intracellular signaling domain. Claim 2: The chimeric antigen receptor according to claim 1, wherein the binding domain specifically bound to ErbB3 is a single chain variable fragment (scFv) of an anti-ErbB3 antibody, comprising: a selected heavy chain CDR1 from the group consisting of SEQ ID Nos. 1, 9, 17, 25 and 33, a heavy chain CDR2 selected from the group formed by SEQ ID Nos. 2, 10, 18, 26 and 34, a heavy chain CDR3 selected from the group formed by SEQ ID NO: 3, 11, 19, 27 and 35, a light chain CDR1 selected from the group consisting of SEQ ID NO: 4, 12, 20, 28 and 36, a light chain CDR2 selected from the group consisting of SEQ ID NO: 5, 13, 21, 29 and 37, and a light chain CDR3 selected from the group consisting of SEQ ID NOs 6, 14, 22, 30 and 38. Claim 3: The chimeric antigen receptor according to claim 1, in which that the binding domain specifically bound to ErbB3 is a single chain variable fragment (scFv) of an anti-ErbB3 antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 7, 15, 23, 31 and 39. Claim 4: The chimeric antigen receptor according to claim 1, wherein the binding domain that specifically binds ErbB3 is a single chain variable fragment (scFv) of an anti-ErbB3 antibody comprising a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 8, 16, 24, 32 and 40. Claim 5: The chimeric antigen receptor according to claim 1, wherein the extracellular binding domain It further comprises at least one of a signal peptide and/or a hinge. Claim 6: The chimeric antigen receptor according to claim 5, wherein the signal peptide is a CD8 signal peptide. Claim 7: The chimeric antigen receptor according to claim 5, wherein the hinge comprises a hinge of CD28 or CD8. Claim 8: The chimeric antigen receptor according to claim 1, wherein the transmembrane domain is selected from the group consisting of an alpha (a), beta (b) or zeta (z) T cell receptor (TCR) chain, CD28, CD3 epsilon (e), CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. Claim 9: The chimeric antigen receptor according to claim 1, wherein the intracellular signaling domain comprises: a primary signaling domain selected from the group consisting of T cell receptor (TCR) zeta (z), FcR gamma (g) , FcR beta (b), CD3 gamma (g), CD3 delta (d), CD3 epsilon (e), CD3 zeta (z), CD5, CD22, CD79a, CD79b and CD66d; and/or a costimulatory signaling domain selected from the group consisting of CD2, CD7, CD27, CD28, CD30, CD40, 4-1BB (CD137), OX40 (CD134), CDS, ICAM-1, ICOS (CD278), LFA- 1 (CD11a/CD18), GITR, MyD88, DAP10, DAP12, 5 PD-1, LIGHT, NKG2C, B7-H3, and a ligand specifically bound to CD83.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210066590A KR102666554B1 (en) | 2021-05-25 | 2021-05-25 | Receptor Tyrosine-protein Kinase ErbB3-Specific Chimeric Antigen Receptor and Immune Cell Expressing the Same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125935A1 true AR125935A1 (en) | 2023-08-23 |
Family
ID=84228993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101354A AR125935A1 (en) | 2021-05-25 | 2022-05-20 | ERBB3-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL THAT EXPRESSES THE SAME |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR102666554B1 (en) |
| AR (1) | AR125935A1 (en) |
| TW (1) | TW202246311A (en) |
| WO (1) | WO2022250440A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102644398B1 (en) * | 2023-01-06 | 2024-03-07 | 의료법인 명지의료재단 | Immuno Anticancer Composition Containing Rhus Veniciflua Strokes Extract And Cytokine Induced Killer Cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107523545A (en) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | A kind of lethal cell of high efficiency stable expression antibody and application thereof |
| KR101927732B1 (en) * | 2017-05-31 | 2018-12-11 | 주식회사 이수앱지스 | Pharmaceutical composition including antibody specifically binding to ErbB3 for preventing or treating drug-resistance cancer and method using the same |
| WO2019091478A1 (en) * | 2017-11-10 | 2019-05-16 | Chineo Medical Technology Co., Ltd. | Modified immune cells and uses thereof |
| AU2018370195B2 (en) * | 2017-11-14 | 2022-01-13 | Green Cross Lab Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109971725B (en) * | 2017-12-28 | 2024-02-02 | 上海细胞治疗研究院 | Antibody-modified chimeric antigen receptor-modified T cells and uses thereof |
| EP3581200A1 (en) * | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
-
2021
- 2021-05-25 KR KR1020210066590A patent/KR102666554B1/en active IP Right Grant
-
2022
- 2022-05-20 AR ARP220101354A patent/AR125935A1/en unknown
- 2022-05-25 TW TW111119522A patent/TW202246311A/en unknown
- 2022-05-25 WO PCT/KR2022/007396 patent/WO2022250440A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| KR102666554B1 (en) | 2024-05-20 |
| TW202246311A (en) | 2022-12-01 |
| WO2022250440A1 (en) | 2022-12-01 |
| KR20220159507A (en) | 2022-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021094037A5 (en) | ||
| JP2019523301A5 (en) | ||
| RU2017105160A (en) | TREATMENT OF CANCER USING THE CHIMER ANTIGENIC RECEPTOR TO CD33 | |
| JP2020517295A5 (en) | ||
| RU2017108903A (en) | CHIMER ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN TREATMENT OF MALIGNANT TUMORS | |
| RU2018109426A (en) | CHIMERIC ANTIGENIC RECEPTORS WITH INTEGRATED CONTROLLED FUNCTIONS | |
| JP2017524367A5 (en) | ||
| JP2020533958A5 (en) | ||
| JP2018538339A5 (en) | ||
| RU2017105065A (en) | TREATMENT OF MALIGNANT NEW FORMATION USING A HUMANIZED CHIMERIC ANTIGENIC RECEPTOR AGAINST VSMA | |
| RU2017105161A (en) | TREATMENT OF CANCER USING THE CHIMER ANTIGENIC RECEPTOR CLL-1 | |
| HRP20201906T1 (en) | Tagged chimeric effector molecules and receptors thereof | |
| JP2020511529A5 (en) | ||
| JP2018527014A5 (en) | ||
| JP2019525956A5 (en) | ||
| JP2017513818A5 (en) | ||
| JP2018535701A5 (en) | ||
| JP2018525033A5 (en) | ||
| PE20231643A1 (en) | COMBINED CHIMERIC ANTIGEN RECEPTOR DIRECTED AT CD19 AND CD20 AND APPLICATIONS THEREOF | |
| RU2018111462A (en) | CHIMERIC ANTIGENIC RECEPTORS TARGETED ON B-CELL MATTERING ANTIGEN | |
| HRP20220767T1 (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor | |
| JP2019532017A5 (en) | ||
| AR125935A1 (en) | ERBB3-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL THAT EXPRESSES THE SAME | |
| JP2017518071A5 (en) | ||
| RU2019128921A (en) | ANTIBODY TO IL-13RA2 AND ITS APPLICATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |